<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Families at high risk for <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> can effectively be recognised by microsatellite instability (MSI) testing </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of the present study is to compare the effectiveness of a MSI test for the identification of <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> in patients selected by a pathologist mainly based on young age at diagnosis (MSI-testing-indicated-by-a-Pathologist; MIPA), with that of patients selected by a clinical geneticist mainly based on family history (MSI-testing-indicated-by-Family-History; MIFH) </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with a <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> associated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> were selected using MIPA (n=362) or MIFH (n=887) </plain></SENT>
<SENT sid="3" pm="."><plain>Germline DNA mutation testing was performed in 171 out of 215 patients (80%) with a MSI positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>MSI was tested positive in 20% of the MIPA-group group compared to 16% in the MIFH-group (P=0.291) </plain></SENT>
<SENT sid="5" pm="."><plain>In 91 of 171 patients with MSI positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> tested for germline mutations were identified as <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> patients: 42% in the MIPA-group and 56% in the MIFH-group (P=0.066) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) or <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e> (EC) presenting at an age below 50 years would have led to the diagnosis of <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> in 89% of these families (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> below 50 years: 88% and EC below 50 years: 12%) </plain></SENT>
<SENT sid="7" pm="."><plain>Families detected by MIPA were characterised more often by extracolonic <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, especially EC (P&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Our results indicate that recognition of <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> or EC below 50 years is as effective as a positive family history </plain></SENT>
<SENT sid="9" pm="."><plain>Families from patients selected by individual criteria more often harbour extracolonic <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>